Cambrex (PRIVATE.CBM)

Overall impact
B (76)

Commentary

Cambrex is a strong overall performer. With a 'B' rating of 75.8 for overall impact (90th percentile compared to all companies), Cambrex ranks 10th out of 52 industry peers, behind Agilent, Usana Health Sciences, Illumina and 6 others, and ahead of LGC Group, Pace Analytical Services, Eversana and 39 others. On top material causes for Cambrex's industry (Life Sciences Tools & Services), Cambrex performs well in Child and Maternal Health (88.1 score), Improved Mental Health (95.1), Disease Eradication (96.1) and 5 other causes where it received an 'A' score and performs poorly in Accountable Institutions (34.9 score), Accountable Institutions (34.9) and Accountable Institutions (34.9).
Screens
Fur
Impact
Cause PRIVATE.CBM
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2,000
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
#<Country/State:0x0000ffff2653c098>, United States
Share classes
PRIVATE.CBM
Description
Provider of contract manufacturing services intended for the pharmaceutical lifecycle. The company offers expertise in drug-substance development, analytical testing, continuous-flow processing, LPPS, and stability storage, enabling global biopharma clients to accelerate growth and manufacturing efficiently.
Material causes
Ethos considers the following causes material for Cambrex, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.